Navigation Links
Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation
Date:5/13/2010

Lumenis has signed a 3-year agreement with a 2 year extension option with Novation the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances and nearly 15,000 members of Provista, LLC.

Santa Clara (Vocus) May 14, 2010 -- Lumenis Ltd., a global leader in developing, manufacturing and distributing a broad range of high-end medical lasers and energy delivery equipment for surgical, ophthalmic and aesthetic applications, has signed a 3-year agreement with a 2 year extension option with Novation the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances and nearly 15,000 members of Provista, LLC.

Novation’s selection of Lumenis as a preferred vendor reflects Novation’s ongoing recognition of Lumenis’s provision of quality products that demonstrate broad-based clinical acceptability at the optimal total value for their members. The versatility of products and the broad diversity of clinical applications enable both hospital and office based physicians to treat a growing number of conditions with CO2, Holmium, SLT, Green, Yellow, Red, IPL, and Diode laser technology.

Lumenis will also be providing the technical service contracts for the current installed base of the members served by Novation throughout the U.S. as well as the new systems purchased through the new 3-year agreement.

“Lumenis is proud to partner with Novation, a recognized leader in supply chain management, innovation, and driving value added programs for its customers. Novation’s ability to provide 90% of health organization product needs, in addition to their national coverage supporting 47% of the nation’s surgical procedures, underscores the importance of the relationship between Lumenis and the nation’s largest healthcare supply company”,, said Caroline Coyle, VP and GM, Lumenis Surgical.

About Lumenis
Lumenis, one of the world’s largest medical laser companies, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has nearly 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning “Light of Life” highlighting the light which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to: www.lumenis.com

About Novation
Founded in 1998, Novation is the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances and nearly 15,000 members of Provista, LLC. Novation offers its customers contract development and management, supply chain data and measurement, and industry knowledge and advocacy. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 500 suppliers. VHA, UHC and Provista members used Novation contracts to purchased nearly $35.7 billion in 2008.

Contact
Michelle Maydan               
Director Corporate Communications                  
1-866-569-0597; 972-4--9599004      
e-mail: mmaydan@lumenis.com


Certain statements and information in this press release may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan”, “project” or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled “Risk Factors”, as well in our reports on Form 6-K, filed with the Securities and Exchange Commission

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb3998424.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lumenis to Showcase Latest Innovations at the 30th Annual American Society for Laser Medicine and Surgery Meeting (ASLMS) in Phoenix, Arizona
2. MU awarded $8.5 million to explore tiny vessels role in cardiovascular diseases
3. Therapure Awarded $4.2 Million BIP Grant from the Ontario Government
4. LA BioMed awarded research grant to study HIV prevention gel
5. £3M awarded for climate model to predict disease outbreak
6. Onyx M.D. Awarded GSA Schedule Contract Creating Increases Access to Government Physician Jobs
7. OHSU awarded $5.8 million to expand health information technology education
8. SWOG cancer trials network awarded over $120 million in NCI grants
9. Semel Institute awarded $15M to establish new integrative phenotyping center
10. Canadian research team awarded international grant for work on Indigenous peoples health
11. Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , ... February 27, 2017 , ... ... transplantation therapy, is proud to announce a new informational post on robotic hair ... Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards & ... International Social Design Awards. , The 7th A' Social Design Award is ... Institutions worldwide with realized projects and conceptual works. , The first phase of ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a ... Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based on ... IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales process ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide ... with a specific LRRK2 mutation, according to a study released today at the ... evidence of a link between pesticides and incidence of sporadic PD through occupational ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release ... show in Cannes (France), XO Private has initiated a second print-run of its lavish ... almost a metre across when open, weighs in at more than six kilos, retails ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
(Date:2/27/2017)... , February 27, 2017 A recent research ... medical marijuana market alone is expected to reach a value of ... along with 28 states have legalized marijuana for medical ... Florida , North Dakota , ... were approved to use the drug in medical applications such as ...
(Date:2/27/2017)... PETACH TIKVAH, Israel , Feb. 27, ... a leading developer of adult stem cell technologies for ... S. Almenoff , M.D., Ph.D., FACP, and Arturo ... Directors.  "Dr. Almenoff and Mr. Araya ... at an exciting time for our company," said ...
Breaking Medicine Technology: